Renaissance Technologies’s Royalty Pharma RPRX Stock Holding History

Renaissance Technologies’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$109M	Buy	1,935,800 +1,144,863	+145%	+$59.6M	0.15%	137
2026 Q1	$37.9M	Buy	+790,937	New	+$34.6M	0.06%	409
2024 Q2	–	Sell	-10,190	Closed	-$309K	–	3893
2024 Q1	$309K	Buy	+10,190	New	+$300K	﹤0.01%	3080
2023 Q4	–	Sell	-483,200	Closed	-$13.1M	–	4066
2023 Q3	$13.1M	Sell	483,200 -287,500	-37%	-$8.54M	0.02%	766
2023 Q2	$23.7M	Sell	770,700 -530,200	-41%	-$18M	0.03%	599
2023 Q1	$46.9M	Buy	1,300,900 +431,900	+50%	+$16M	0.06%	369
2022 Q4	$34.3M	Buy	+869,000	New	+$36.3M	0.05%	470
2022 Q2	–	Sell	-183,900	Closed	-$7.17M	–	4517
2022 Q1	$7.17M	Sell	183,900 -615,200	-77%	-$24.2M	0.01%	1348
2021 Q4	$31.8M	Buy	799,100 +15,500	+2%	+$602K	0.04%	484
2021 Q3	$28.3M	Sell	783,600 -45,000	-5%	-$1.75M	0.04%	521
2021 Q2	$34M	Buy	+828,600	New	+$35.2M	0.04%	487

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies's RPRX Position: Q2 2026 in Review

Renaissance Technologies increased its Royalty Pharma (RPRX) stake by 145% in Q2 2026, buying an estimated $59.6M and bringing the position to 1,935,800 shares worth $109M. The position accounts for 0.15% of the portfolio, ranked #137.

Renaissance Technologies first reported a position in RPRX in Q2 2021 and has held it in 11 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Renaissance Technologies held 1,935,800 shares of Royalty Pharma worth $109M as of Q2 2026.
Renaissance Technologies bought 1,144,863 Royalty Pharma shares in Q2 2026, an estimated $59.6M.
Royalty Pharma made up 0.15% of Renaissance Technologies's portfolio in Q2 2026, its #137 holding.
Renaissance Technologies first reported a position in Royalty Pharma in Q2 2021 and has held it in 11 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.